此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项针对年龄≥2至<12岁、疑似或确诊细菌感染或接受预防性抗生素治疗的儿科受试者的研究

2026年9月25日 更新者:GlaxoSmithKline

一项1期、开放标签、单臂(非对照)研究,旨在评估口服吉泊达星单次剂量联合抗菌标准治疗在2岁至小于12岁疑似或确诊细菌感染或接受抗生素预防的儿科受试者中的药代动力学和安全性

The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment with antibacterials for a confirmed or suspected infection or for its prevention.

研究概览

地位

尚未招聘

条件

研究类型

介入性

注册 (估计的)

25

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • California
      • Orange、California、美国、92868
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Antonio Arrieta
    • Louisiana
      • Shreveport、Louisiana、美国、71101
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Patricia Pichilingue-Reto
    • Maryland
      • Baltimore、Maryland、美国、21827
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • Allison Agwu
    • Missouri
      • St Louis、Missouri、美国、63110-1010
        • GSK Investigational Site
        • 接触:
        • 接触:
        • 首席研究员:
          • David Hunstad

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 11年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participants having ≥2 to <12 years of age at the time of signing the informed consent/assent and have a body weight >=10 kilograms (kg).
  • Participants receiving SoC antibacterial therapy for a confirmed/suspected infection or for prophylaxis AND is able to take a single dose of the powder for oral suspension formulation of gepotidacin after a meal.
  • Participants either hospitalized or in an overnight clinic. Participant is expected to be in hospital/clinic for at least 24 hours post administration of study intervention.

Participant has an indwelling venous catheter in place as part of the clinical SoC.

  • Male or female according to their reproductive organs at birth.
  • Pregnancy testing is required as appropriate for the age, sexual activity, and sexual maturity of pediatric participants and as required by local regulations. Investigator should apply clinical judgment.
  • A female participant is eligible to participate if she is a WOCBP who is not pregnant as confirmed by a high sensitivity serum or urine pregnancy test at baseline (Day 1) regardless of current or prior contraception use or abstinence, is not breastfeeding, or is not a WOCBP.
  • Participant LAR(s) who has the ability to understand, agree to, and sign the informed consent form before initiation of any protocol-related procedures; participant has the ability to give documented assent.
  • Participant and participant's LAR are willing and able to comply with study instructions, study visits, and procedures.

Exclusion Criteria:

  • Participants having a BMI-for-age that is less than the 5th percentile or greater than the 95th percentile based on the CDC percentiles [CDC NCHS Growth Charts].

  • Participants having a clinically significant medical history, including malignancy, significant chromosome abnormality, neurological disorder or history of seizure (excluding simple febrile seizure), chronic immunosuppressive disease, active tuberculosis or acute hepatitis.

  • Participants with serious disease/condition that could be imminently life-threatening (e.g. is clinically/hemodynamically unstable, is septicemic, has severe sepsis, organ failure, requiring ITU care or has clinical laboratory tests either nonstable or anticipated to be nonstable) or the participant is unlikely to survive for the duration of the study period.

  • The participant has severe renal organ dysfunction or has known anuria, oliguria, or significant impairment of renal function (creatinine clearance <60 mL/min or clinically significant elevated serum creatinine as determined by the investigator).

  • The participant has a significant CV history or based on investigator judgment any clinically significant abnormal ECG reading at Screening/baseline (e.g., prolonged QT syndrome).

  • The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of complications (e.g., uncontrolled diabetes in the judgment of the investigator, transplant recipients (with the exception of cornea and autologous BMT), participants with clinically significant persistent granulocytopenia [absolute neutrophil count <1000/μL], and participants receiving immunosuppressive therapy, including corticosteroid therapy at a dose of >1 mg/kg/day of prednisolone or equivalent for >1 week or 0.5-<1 mg/kg/day prednisolone or equivalent for >2 weeks). Participants aged ≥6 years with a known CD4 count of <200 cells/mm3 and participants aged <6 years with a known CD4 count of <500 cells/mm3 are to not be enrolled.

  • The participant has any of the following medical condition that requires medication that may be impacted by inhibition of acetylcholinesterase, such as:

    • Poorly controlled asthma or obstructive pulmonary disease at baseline and, in the opinion of the investigator, not stable on current therapy.
    • Active peptic ulcer disease
    • Juvenile Parkinson disease
    • Juvenile Myasthenia gravis
  • The participant has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study intervention (e.g., ileostomy or malabsorption syndrome).

  • The participant plans to use any of the prohibited medications or nondrug therapies from the Baseline Visit through Follow-up Visit at 7 ±3 days after the single dose of study intervention.

  • The participant has received a prohibited medication within 14 days or 5 half-lives prior to gepotidacin administration, whichever is longer.

  • The participant has been previously enrolled in this study or has previously been treated with gepotidacin.

  • The participant has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives prior to gepotidacin administration, whichever is longer.

  • The participant, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.

  • If the child is being breastfed:

    • There is suspicion of current alcohol or substance misuse/abuse in breastfeeding mother.
    • The breastfeeding mother is taking any medication or any substances containing any of the medications included in the prohibited medication list with known or unknown lactation excretion.
  • The participant has severe hepatic organ dysfunction.

  • The participant has an ALT value >2 × ULN.

  • The participant has a total bilirubin >1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is ≤1.5xULN.

  • Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.

  • The participant has congenital long QT syndrome or known prolongation of the QTc interval.

  • The participant has uncompensated heart failure.

  • The participant has severe left ventricular hypertrophy.

  • The participant has a family history of QT prolongation or sudden death or history of sudden infant death in a sibling.

  • The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.

  • The participant is taking QT-prolonging drugs or drugs known to increase the risk of TdP per the ww.crediblemeds.org. "Known Risk of TdP" category at the time of the Baseline Visit, which cannot be safely discontinued from the Baseline Visit (Day 1) through 7 (+3) days after the single dose of study intervention; or the participant is taking a strong CYP3A4 inhibitor.

  • The participant has a mean triplicate QTc >450 msec or a mean triplicate QTc >480 msec for participants with complete bundle branch block.

  • The participant has a documented or recent history of uncorrected hypokalemia within the past 3 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Gepotidacin plus Standard of care (SOC)

Single Arm

Gepotidacin will be administered

SOC will be administered

研究衡量的是什么?

主要结果指标

结果测量
大体时间
吉泊达星从零时到末次可定量浓度时间的药时曲线下面积(AUC[0-t])
大体时间:给药后24小时内(第1天)
给药后24小时内(第1天)
吉普替拉辛从零时间外推至无限时间的浓度-时间曲线下面积(AUC[0-inf])
大体时间:给药后最长24小时(第1天)
给药后最长24小时(第1天)
吉泊达星的最大观察血浆浓度(Cmax)
大体时间:给药后最多24小时(第1天)
给药后最多24小时(第1天)
吉泊达星的表观口服清除率(CL/F)
大体时间:给药后最多24小时(第1天)
给药后最多24小时(第1天)
吉泊达星的表观分布容积 (Vz/F)
大体时间:给药后最长24小时(第1天)
给药后最长24小时(第1天)
吉泊达星终末相半衰期(t1/2)
大体时间:给药后24小时内(第1天)
给药后24小时内(第1天)

次要结果测量

结果测量
大体时间
出现不良事件(AEs)、特别关注不良事件(AESI)和严重不良事件(SAEs)的参与者数量
大体时间:最多7天 (±3天)
最多7天 (±3天)
生命体征相对于基线的变化:体温
大体时间:给药后2小时(±15分钟),第1天
给药后2小时(±15分钟),第1天
生命体征相对于基线的变化:血压
大体时间:在给药后2小时(±15分钟),第1天
在给药后2小时(±15分钟),第1天
生命体征较基线的变化:脉搏率
大体时间:在第1天给药后2小时(±15分钟)
在第1天给药后2小时(±15分钟)
与基线相比心电图(ECG)的变化
大体时间:在给药后第1天的2小时(±15分钟)
在给药后第1天的2小时(±15分钟)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月18日

初级完成 (估计的)

2027年8月23日

研究完成 (估计的)

2027年8月23日

研究注册日期

首次提交

2026年1月19日

首先提交符合 QC 标准的

2026年1月19日

首次发布 (实际的)

2026年1月28日

研究记录更新

最后更新发布 (实际的)

2026年9月28日

上次提交的符合 QC 标准的更新

2026年9月25日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • 222778
  • 2025-522916-17 (EudraCT编号)
  • 2025 (美国 NIH 拨款/合同)
  • HSSO100201300011C (其他标识符:BARDA Agreement number)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

IPD 共享时间框架

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 共享访问标准

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅